Connect with us

Breaking

Here are our three top medical technology companies for 2018

Published

on

Prev1 of 2
Use your ← → (arrow) keys to browse

(FinancialPress) – It’s 2018, and once again, the market is in love with medical technology.

Medical devices -the med-tech sector- have been a top performer for the last five years running. Even better than biotech. And 2018 is more of the same.

The med-tech bull is loose again!

Medical devices beat the S&P by 103%, trounce biotechs, too!

You Know Where to Go, Now Zero In

There’s never been a better way to scoop up winners than to find the best companies in the market’s hottest sectors.

That’s why you should turn your attention to Zenosense, Inc. (OTCQB: ZENO), Thermo-Fisher (NYSE: TMO)and Merit Medical Systems (NASDAQ: MMSI).

This is how it goes when med-tech is running high… Look at these gains in less than two years!

  • AxoGen is up 512% in 21 months
  • Novocure is up 266% in the last 14 months 2017
  • Cutera has risen 372% in the past 20 months

And you don’t have to wait for winners, either. The S&P 500 is down 1% to start 1Q 2018, but 26 med-tech stocks are already showing off double-digit gains!1

Take Heart with This…

If you are drawn to potential like this, it doesn’t get any more exciting than
Zenosense, Inc. (OTCQB: ZENO).

Zenosense, through a joint venture ownership in MIDS Medical Ltd, is developing a revolutionary hand-held device to diagnose heart attacks when the chance to save lives is greatest — in the first minutes of the golden hour, as soon as it happens.

This is “point-of-care” technology, the best possible medical approach. It means that whoever responds to a cry for help, paramedics, an emergency clinic, rescue squad, or nurse, can use the Zenosense device to put the patient on the right track within minutes. No need to wait as the clock ticks down for lab tests to come back, no need to worry during a 20–30-minute ambulance ride to wonder what’s really happening.

On June 19, the company released news of breakthrough quantitative product testing results. It was the culmination of seven months work. ZENO “watchers” were primed to buy…and when ZENO shares opened at around 27¢ that day…they started buying.

What happened next was breathtaking; ZENO soared from 27¢ at open to closeat 55¢

Shareholders doubled their money in just one day!

And here’s the kicker…the following day ZENOhit a high of 77¢, which pushed it to a triple off the prior day’s open of 27¢!

It doesn’t happen like this every time, but when it does, you can lock in some impressive gains very quickly!

And just so you know, despite this big two-day gain, we see massive upside potential in Zenosense as it moves ever closer to a final product announcement. Now may be the ideal time to consider a position in ZENO…at a minimum, make sure that ZENO is on your watch list.

Now could be the ideal time to jump in; we believe the company has already achieved key milestones in its R&D.

Previous Milestones

(Mar, 17): Zenosense, Inc.: MIDS Medical Engages Future Diagnostics for Assay Consulting Services

(Jun, 2017): Zenosense, Inc. has received notice of a patent issuance in the U.S.

(Jul, 2017): Zenosense, Inc. — MIDS Hybrid Strip Detection Testing to Commence

These R&D milestones set the foundation for recent achievements that have firmly validated the company’s technology and moved it well along toward final stages of product development and market release.

Recent Milestones

(Nov, 2017): Zenosense, Inc.: MIDS Hybrid Strip — Successful Initial Test Results

(Jun, 2018): Zenosense, Inc.: Breakthrough Quantitative MIDS Testing Results

At this point we see these announcements as key signals to investors. Zenosense now appears poised for the kind of explosive growth that we reference above. We therefore recommend you consider ZENO as an immediate buy.

For more conservative investing in medical technology, we also recommend you consider two other healthcare opportunities. The first is an established blue-chip industry leader ThermoFisher (TMO) and the second a reliable growth-oriented mid-cap stock like Merit Medical Systems (MMSI).

ThermoFisher is a leading scientific research company that is incorporating advances in genetics into its diagnostic tools. We see tremendous upside in this arena. Further, ThermoFisher’s leadership across in multiple medical technologies makes it a reliable long-term play — but also consider that this company could be a nice 25%-30% gainer in 2018.

Merit Medical Systems (MMSI) makes disposable medical devices used particularly in cardiology, radiology and endoscopy procedures. Medical disposables have such high margins that some medical device makers earn more on the supplies for their machines than they do on the hardware itself. MMSI also has good potential for 25% to 30% before the year is out.

What to do now…

Do your homework of course. Put these three companies on your Watch List so you will get bulletins each time they make news!

But don’t dither waiting for lightening to strike. You’ll get burned that way. Med-tech stocks can move strongly and suddenly upward on good news.

ZENO’s Market Potential and Position Among the Competition

The global market for cardiac biomarker diagnostic tests is projected to reach $7.2 billion by 2018.

Several other companies are working to overcome the slow turnaround time for results from laboratory analyzers, including Abbott (NYSE:ABT), Roche (SIX:ROG), Alere (NYSE:ALR), and Trinity Biotech (NASD:TRIB). But none of them promises a true high-sensitivity instrument for instantaneous point of care diagnostics like the Zenosense MIDS Cardiac device is developing now.

For example Abbott (now the largest diagnostic company in the world with their acquisition of Alere) acquired i-Stat Corporation for $392 Million in 2003, (an amount which represents over 30X Zeno’s current value!).

i-Stat Corporation specialized in a hand-held blood analyzer for bedside testing and Abbott launched the i-Stat Troponin-I test for cardiac events in 2004. But that doesn’t mean it’s a true competitor to ZENO, because I-Stat cannot match the results of state of the art laboratory analyzers during the early onset of symptoms.

Even with that limitation, the need is so great that i-Stat is now Abbott’s leading handheld device and is used in more than one-third of all U.S. hospitals and emergency rooms.5 Imagine what will happen when a truly accurate ZENO device could be available!

ZENO Is Unique

Being developed to be considerably more accurate that the i-Stat… ZENO’s device is a standout among massive competition.

For instance, Trinity Biotech, which claimed its device was “significantly more accurate than the current established point-of-care tests in the market”6 applied for FDA approval, but it didn’t go well. At the FDA’s request, Trinity abandoned its pursuit, admitting its device could not match the performance of the most recently cleared laboratory analyzer.

That leaves an enormous market opportunity ahead for a device like MIDS Cardiac™, which would not only deliver rapid results but become the first device on the market that also delivers true high sensitivity results equal or exceeding laboratory accuracy.

Headquartered at Sci-Tech Daresbury, a world-class science and innovation campus located in the UK the ZENO development team has over thirty years cumulative experience in magnetic sensors in the medical and bioengineering field.

Faster growth — Sci-Tech Daresbury companies have seen sales grow at 30%/year over the past 5 years

More investment — Daresburg companies raised over 80m to date.

500 new products and services in the last 4 years

Incorporating the patented MIDS technology, MIDS Cardiac™ uses highly sensitive, custom built “Hall Effect” magnetic sensors embedded within a disposable microfluidic test strip as a “Lab-On-Chip” device.

This can detect extremely low levels (nano-Tesla) of magnetic field disturbance caused by the test particles used in immunoassay tests. That is what makes MIDS Cardiac™ different from anything else on the market. Detection at these levels is unheard of and should allow accuracy and speed of results, which will significantly accelerate the triage, diagnosis, treatment and disposition of patients reporting chest pain and with suspected AMI.

That’s why the ZENO team scientists give this small company such an edge:

Nasser Djennati
Chief Scientific Officer
MIDS Medical Ltd.

20 years expertise in Hall Effect technology and magnetic field measurement

Nanoparticle and sensor design for bio-medical and bio-sensing medical Point of Care devices.
We’ve already told you the MIDS device is striving to achieve gold-standard results right at the point of care. That alone will make it unique and open a huge slice of the cardiac healthcare market to ZENO.

But there’s a lot more behind this product’s likely future success that makes it a game changer for emergency medicine:

A game-changing Point of Care sensitivity and accuracy improvement, equal or superior to high sensitivity cardiac biomarker assays performed on central laboratory analyzers

Patient friendly, tiny finger prick sample rather than treated venous blood draw

An industry leading tiny 5 microliter blood sample, 3 to 400 times smaller (1 assay) than existing Point of Care devices for cardiac marker tests

Test times 3 to 7 times faster (1 assay) than existing Point of Care devices

Capable of 3 multiplexed assays (3 cardiac biomarkers in a single test strip)

Automated operation by minimally trained personnel even in an ambulatory setting

Considerably more cost effective for healthcare providers than existing test devices

Conclusion — There Are Three Great Stocks Here

We like Thermo Fisher, especially for a conservative portfolio. And we believe MMSI’s growth rate should help it to do very well this year, though we have less faith in the longer term.

But we think investors looking for a home run should be excited about ZENO’s prospects.

We believe that a technology that can match or exceed state-of-the-art laboratory accuracy and deliver results rapidly in a cost-effective device the size of an average smart phone will be in universal demand. That’s what ZENO is promising, and could deliver.

Not only would ZENO’s device, the MIDS Cardiac™ meet a critical medical need for the first time, it would undoubtedly attract a very substantial valuation.

Here, i-Stat serves as a useful aid for diagnosis. Its device falls well short of the state of the art laboratory analyzers, and yet, it can command a price tag of nearly $400 million. That suggests that an enormous valuation for MIDS Cardiac™ is achievable.

If the MIDS Cardiac device succeeds as we expect, the long term could be even more dynamic. By adapting the MIDS technology to numerous other immunoassay tests, ZENO could access a market that is projected to be worth $23.7 billion per year worldwide by 2019.

With unheard accuracy levels and industry leading features on every level MIDS Cardiac™ is a true blockbuster in the making and ZENO has potential to be the high growth stock of 2018 and way beyond.

For news releases from Thermo Fisher, go to:
http://ir.thermofisher.com/investors/contact-information/email-alerts/default.aspx

For news releases from Merit, go to:
https://www.merit.com/investors/investor-information-request/

For news releases from ZenoSense, go to:
https://www.zenosense.com/investors-info

DISCLAIMER

This financial news and information portal (newbiotechstock.com), and/or our newsletters contain commercial advertisements, and are for general entertainment purposes only. Along with the aggregation of timely financial news, we are engaged in the business of analyzing, marketing and advertising companies for monetary compensation. Unless otherwise stated below, the paying Third Party for our services may own shares and may liquidate them during any and all advertising periods. This disclaimer is to be read and fully understood before using newbiotechstock.com, or joining one of our newsletter/email lists. We also encourage you to read the SEC INVESTOR ALERT before reading content found on newbiotechstock.com and/or our newsletters. You are reading content found on our financial news and informational portal because you have clicked on an advertisement found on one of many marketing channels we advertise on. newbiotechstock.com is for entertainment purposes only. We are NOT a source of unbiased information. Never invest in any stock featured on our site or newsletters unless you can afford to lose your entire investment. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled on the website/newsletter and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead, newbiotechstock.com strongly urges you to supplement the information obtained from this website/newsletter with a complete and independent investigation of the companies discussed and a consideration of all pertinent risks. Investing in securities, including the securities of the companies profiled or discussed on this website/newsletter, is highly speculative and carries a high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies discussed. The information found on newbiotechstock.com, and/or our newsletters are based on sources, which we believe to be reliable, but are not guaranteed by us as being accurate and do not purport to be a complete statement or summary of the available data. newbiotechstock.com encourages readers and investors to supplement the information found on our site or in our newsletters with independent research and other professional advice. All information on featured companies is provided by the companies profiled through their website, news releases, and corporate filings, or is available from public sources. newbiotechstock.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the featured companies None of the owners of newbiotechstock.com, or any of its directors, officers, employees, contractors, or affiliates is a licensed broker-dealer, account representative, market maker, investment banker, investment advisor, analyst or underwriter in any jurisdiction whatsoever. newbiotechstock.com does not offer such advice or analysis, and newbiotechstock.com further urges you to consult your own independent tax, business, financial and investment advisors before purchasing or selling any securities of the companies discussed on this website/newsletter. Compensation: newbiotechstock.com may be compensated for up to one hundred thousand USD via bank wire by a third party for continuous analyzing, marketing and advertising services. newbiotechstock.com does not own any shares of any featured company. The paying third party may own shares and may sell all, any or none of any shares held in any featured company during advertisement periods, which may negatively affect the featured company’s stock price. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the featured company. newbiotechstock.com and its employees, contractors, officers, directors, or affiliates may purchase shares on the open market of any mentioned featured company during advertisement periods and following the dissemination of any newsletters. This is an inherent conflict of interest. The services provided by this website/newsletter and its contents are provided “as is” and newbiotechstock.com makes no representations or warranties of any kind with respect to this website/newsletter, its contents or its services. This website/newsletter has been prepared solely for the purpose of providing information about newbiotechstock.com and the services it offers. This website/newsletter has been compiled in good faith by newbiotechstock.com. newbiotechstock.com assumes no liability or responsibility for any errors or omissions in the content of this website/newsletter, any failures, delays, or interruptions in its services or any content contained on this website/newsletter, any losses or damages arising from the use of the content provided on this website/newsletter, or any conduct by users of newbiotechstock.com’s services. newbiotechstock.com reserves the right to add, modify or delete any information at this website/newsletter at any time. This website/newsletter may contain “forward-looking” information within the meaning of the Private Securities Litigation Reform Act of 1995. In accordance with the safe harbor provisions of this Act, statements contained herein that look forward in time that includes everything other than historical information, involve risks and uncertainties that may affect the companies’ actual results. There can be no assurance that such statements will prove to be accurate and there are a number of important factors that could cause actual results to differ materially from those expressed in any forward-looking statements made in this report. Further specific financial information, filings, and disclosures as well as general investor information about the profiled companies, advice to investors and other investor resources are available at the Securities and Exchange Commission (“SEC”) website www.sec.gov and the Financial Industry Regulatory Authority (“FINRA”) website at www.finra.org.newbiotechstock.com undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events, or otherwise. In addition to information about the company discussed, from time to time, this website/newsletter may contain the symbols of companies and/or news feeds or links to websites about companies that are not being discussed by us but are merely illustrative of certain activity in the stock market that we are highlighting (so-called hyperlinks to third party websites or access to third party content). Readers are advised that all links and access to these sites and content solely for informational purposes. newbiotechstock.com, its owners, directors, officers, employees, affiliates, and contractors are not responsible for errors and omissions nor does newbiotechstock.com control, endorse, or guarantee any content found in such sites or content. Any opinions expressed are subject to change without notice. It is also possible that the companies discussed on those sites may not have approved certain or any statements within the report. By accessing or viewing this website/newsletter, you agree that newbiotechstock.com, its owners, directors, officers, employees, affiliates and contractors are not responsible for any content, associated links, resources, or services associated with a third-party website. newbiotechstock.com uses third parties to disseminate information to subscribers. Although we take precautions to prevent others from obtaining our subscriber list, there is a risk that our subscriber list, through no wrong doing on our part, could end up in the hands of an unauthorized party and that subscribers will receive communications from unauthorized third parties. In no event shall newbiotechstock.com, its owners, directors, officers, employees, affiliates and contractors be liable (jointly or severally) for any special, incidental, indirect or consequential damages of any kind, or any damages whatsoever resulting from loss of use, data or profits, whether or not advised of the possibility of damage, and on any theory of liability, arising out of or in connection with this website/newsletter. You agree to hold newbiotechstock.com, its owners, directors, officers, employees, affiliates and contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur arising out of the use of the information contained on this website/newsletter (including any loss or damage of any sort associated with your use of third party content). You agree that use of this website/newsletter is at your sole risk. newbiotechstock.com disclaims all warranties of any kind, express or implied. If any applicable authority holds any portion of this section to be unenforceable, then liability will be limited to the fullest possible extent permitted by applicable law. newbiotechstock.com encourages readers to invest carefully, and read investor and issuer information available at the websites of the SEC. The SEC has launched an investor-focused website to help you invest wisely and avoid fraud at www.investor.gov and filings made by public companies can be viewed at www.sec.gov . In addition, FINRA has published information at its website on how to invest carefully at www.finra.org/investors/index.htm.Questions regarding any information contained on this website/newsletter may be sent to mail@newbiotechstock.com. To review newbiotechstock.com’s website and its disclaimer, please visit www.newbiotechstock.com

Prev1 of 2
Use your ← → (arrow) keys to browse

Breaking

NetCents Technology, Disrupting the Payments Industry

Published

on

(FinancialPress) — It’s been quite the year for cryptocurrency and blockchain. We’ve gone from massive growth and speculation to a market correction and have now entered into a strong, steady growth phase with the emergence of companies that are building the industry’s foundation for future growth. These companies have a solid business and growth plan, a strong go to market strategy, products that differentiate themselves from competitors, and technology that disrupts.  

Not only are we seeing newer companies and innovative startups emerge solving big problems using blockchain, but the growth in the space has attracted major companies like Softbank and IBM’s Watson, blue chip brands such as SAP (SAP:NYSE), BP (BP:NYSE), Samsung, and shipping giant, Maersk, who are now exploring ways to apply decentralized ledger systems and new blockchain technologies to their operations.  

One stand out company that has continued to push the boundaries of innovation, and who has emerged as one of the leaders in this space is NetCents Technologies. NetCents (NC:CSE) is a blockchain and cryptocurrency company that has developed a universal transactional hub for cryptocurrency payments. The platform equips merchants, ISO’s, and payment technology companies with a platform to integrate cryptocurrency payments into their business, accept with zero risk, and empower consumers to spend their currency easily.

The NetCents platform has eliminated the risk and volatility associated with accepting cryptocurrency payments, allowing merchants to be indifferent to the form of payment received. They are now showing signs of becoming an underlying technology layer for other processors and companies wanting to offer these services to their clients, and have proved themselves to be a pioneer in this space as one of the first companies in Canada.

In the past couple of months alone, they have made significant strides rolling out multiple enhancements to their platform and agreements:

  •    Signed a merchant agreement with MindGeek, one of the largest video streaming companies in the world
  •    Announced the launch of their cryptocurrency credit card. Unlike all other cards on the market, prepaid crypto credit cards, theirs will be tied directly into the users wallets, allowing them to spend their cryptocurrency at 40 million merchants worldwide, without having to worry about the value of their crypto fluctuating between the time the user loads it and the time that they spend it.
  •    Launched a merchant marketing campaign to over 1 million merchants worldwide
  •    Added Bitcoin Cash, Verge, Tron, Nem, and Horizon to their merchant gateway
  •    Signed an agreement with SoftPoint. Through this integration, NetCents is now integrated into some of the largest POS and terminal systems: Clover, PAX, Poynt, Ingenico, ExaDigm, Micros, NCR, Squirrel, and Dinnerware to name a few.
  •    Entered into a white-label enterprise agreement with High Risk Commerce. High Risk Commerce will be promoting the NetCents merchant gateway to their hundreds of ISO’s and over 10,000 merchants.

With these large contracts signed, new integrations, and platform enhancements, NetCents is a company that has been able to differentiate themselves, build and grow a strong platform and client base, which has them as one of Canada’s stand outs, and which hasn’t gone unnoticed by some of the biggest players in the tech community in the country.

Just this week, they announced that they had been nominated as Blockchain Company of the Year at the Canadian FinTech & AI Awards, showing that key industry players are taking note of what they have accomplished in a short period of time. Keep your eyes on this one.

Disclaimer:

This content is the view of the author and should not be considered a solicitation to buy or sell stock. Always consult an investment advisor before making any trading decisions. A fee has been paid for the creation and distribution of this content. FinancialPress.com is operated by Stock Social Inc. and owners of which may directly or indirectly own securities in the profiled companies in this article. This presents a potential conflict of interest by the author(s) and information should be considered biased. We do not make claims to any accuracy of the statements within. Always do your own due diligence and consult a registered advisor when making any trading decision. FinancialPress.com does not recommend that the securities profiled should be purchased, sold or held and is not liable for any investment decisions by its readers or subscribers. Information presented by FinancialPress.com may contain “forward-looking statements ” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance, are not statements of historical fact and may be “forward-looking statements.” Forward-looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements may be identified through the use of words such as “expects, ” “will, ” “anticipates,” “estimates,” “believes,” “may,” or by statements indicating that certain actions “may,” “could,” or “might” occur.

 

Continue Reading

Breaking

NetCents Technology Nominated as Blockchain Company of the Year

Published

on

(FinancialPress) — NetCents Technology Inc. (“NetCents” or the “Company“) (CSE: NC/ Frankfurt: 26N), is honoured to be recognized by the Digital Finance Institute as a nominee for Blockchain Company of the Year at the 4thAnnual Canadian FinTech & AI Awards.

The Canadian FinTech & AI Awards are Canada’s largest and most prestigious FinTech event with over 3,000 attendees from the banking, legal, finance, tech, startup, and Blockchain community. The Canadian FinTech & AI Awards were started in 2015 by the Digital Finance Institute to recognize and celebrate Canadian innovation in financial technology and artificial intelligence. The Awards bring together Canada’s leaders in finance to celebrate and support Canadian technology. The Awards gala will be held November 26th in Toronto at the Carlu.

“We’re honoured to receive this recognition and to be nominated for this prestigious award alongside such innovative companies, all of whom push the boundaries every day.,” stated Clayton Moore, CEO at NetCents Technology. “To be recognized by our community like this is an honour and a testament to the dedication and hard work of our team. Congratulations to our fellow nominees and thanks to all the sponsors this year who continue to support technology and innovation in Canada.”

About NetCents

NetCents is a next-generation online payment processing platform, offering consumers and merchants online services for managing electronic payments. The Company is focused on capturing the migration from cash to digital currency by utilizing innovative Blockchain Technology to provide payment solutions that are simple to use, secure and worry free. NetCents works with its financial partners, mobile operators, exchanges, etc., to streamline the user experience of transacting online. NetCents Technology is integrated into the Automated Clearing House (“ACH”) and is registered as a Money Services Business (MSB) with FINTRAC, which ensures our consumer’s security and privacy. NetCents is available for deposits from 194 Countries around the World, providing you with the freedom to choose to Pay. Your Way.™

On Behalf of the Board of Directors
NetCents Technology Inc.

“Clayton Moore”
Clayton Moore, CEO, Founder and Director

NetCents Technology Inc.
Suite 880, 505 Burrard St (Bentall 1),
Vancouver, BC, V7X 1M4

Cautionary Note Regarding Forward Looking Information

This release includes certain statements that may be deemed “forward-looking statements”. All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company’s management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management’s beliefs, estimates or opinions, or other factors, should change.

The CSE has not reviewed, approved or disapproved the content of this press release

SOURCE NetCents Technology Inc.

For further information: please visit the corporate website at www.net-cents.com or contact Gordon Jessop, President / COO at: gord.jessop@net-cents.com.

SOURCE: https://www.newswire.ca/news-releases/netcents-technology-nominated-as-blockchain-company-of-the-year-699933632.html

Continue Reading

Breaking

Uber to settle data breach case for $148 million

Published

on

(FinancialPress) — Ride-hailing service provider Uber has reached an agreement to settle a 2016 data breach case. It will have to pay $148 million to close the investigation, after it was accused of intentionally hiding the event.

The settlement – the largest of its kind in recorded history – will be divided up among the 50 states that levied the case through their attorney generals, and Washington DC, said the NY attorney general.

The issue began when the company was accused of violating state-level notification laws by avoiding to disclose that their users‘ personal information had been stolen in 2016. 57 million people were affected at the time.
It was only in late 2017 that Uber revealed that they had paid off the hackers to destroy the data. The price tag was $ 100,000. Uber settled the FTC investigation on the topic in April.
The settlement compromises Uber to implement a corporate integrity program to incentivize employees to report any activities they deem unethical. It will also have to align itself to model data breach notification and data security practices. Lastly, it will be audited on its data security practices by a third party.

In a press conference, New York attorney general Barbara D. Underwood commented on the settlement: “This record settlement should send a clear message: we have zero tolerance for those who skirt the law and leave consumer and employee information vulnerable to exploitation“. Her state will receive approximately $5.1 million of the payout.

A blog post published by Uber chief legal officer Tony West reads as follows: “Our current management team’s decision to disclose the incident was not only the right thing to do, it embodies the principles by which we are running our business today: transparency, integrity, and accountability. We’ll continue to invest in protections to keep our customers and their data safe and secure, and we’re committed to maintaining a constructive and collaborative relationship with governments around the world.”

 

 

Continue Reading

Most Popular